Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences November 06, 2023 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra‐Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip co
Slide 2: Earnings Presentation Q2 FY24
SeQuent Scientific Limited Earnings Presentation Q2 FY24 6th November, 2023
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 4: Sequent Scientific – Q2 FY24 Earnings Release
Sequent Scientific – Q2 FY24 Earnings Release We continue to progress towards reshaping the business for profitable growth. Our initiatives have begun showing results. Operating margins have expanded this quarter in line with our plans communicated in the prior quarters, as we focus on improving the
Slide 5: Q2 FY24: Key Highlights
Q2 FY24: Key Highlights EU portfolio reshaping progressing well Emerging Markets – India Formulations – Turkey price interventions sequential progress driven Margin improvement by portfolio focus, footprint visible, well placed for next reflecting in margins expansion leg of growth USFDA Audit Proje
Slide 6: Q2 FY24: Revenue Performance – by geography
Q2 FY24: Revenue Performance – by geography All values in ₹ Mn Revenue Distribution Q2 FY24 Q1 FY24 QnQ Gr% Q2 FY23 YoY Gr% H1 FY24 H1 FY23 YoY Gr% Formulations 2,532 2,478 2.2% 2,408 5.2% 5,014 4,866 3.0% Europe 1,191 1,172 1.6% 911 30.7% 2,366 1,959 20.8% Emerging Markets 1,068 1,052 1.5% 1,178 (9
Slide 7: Formulations Q2 FY24: Margin expansion driven by Europe portfolio reshaping and Turkey price hikes
Formulations Q2 FY24: Margin expansion driven by Europe portfolio reshaping and Turkey price hikes Key Updates FDFs 1000+ EUROPE: • Portfolio reshaping and cost initiatives have progressed well – improvement seen in Q2 margins; business well positioned for next leg of growth EMERGING MARKETS: • Limi
Slide 8: API Q2 FY24: Remain focused on profitable growth; seasonal challenges in deworming products
API Q2 FY24: Remain focused on profitable growth; seasonal challenges in deworming products Key Updates Commercial 30+ • During the quarter, our Vizag facility underwent a USFDA inspection with one observation which was APIs procedural in nature, the response to which has already been shared. • Cont
Slide 9: Financials
Financials oN eS
Slide 10: Q2 FY24 Consolidated Financials
Q2 FY24 Consolidated Financials All values in ₹ Mn Particulars Q2 FY24 Q1 FY24 Q2 FY23 YoY% QoQ% H1 FY24 H1 FY23 Revenue from Operations 3,460 3,332 3,376 2% 4% 6,792 6,789 Exceptional item Material Consumption (1,898) (1,948) (1,979) -4% -3% (3,846) (3,946) • Q2 FY24 exceptional Gross Margin 1,562
Slide 11: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹ Mn Particulars Sep-23* Mar-23* • Working capital lower on account of: Shareholders’ Funds 6,317 6,987 • INR ~400mn Turkey translation impact Minority Interest 510 504 • Effective payable management and vendor financing Net Debt 3,593 3,561 Tangible Assets 3,35
Slide 12: For details, feel free to contact
For details, feel free to contact: Krunal Shah Abhishek Singhal Nachiket Kale Company Secretary Investor Relations Consultant Investor Relations Advisor +91 22 4111 4779 abhishek.s@sequent.in +91 9920940808 investorrelations@sequent.in nachiket.kale@linkintime.co.in Registered Office: 301/A, ‘Dosti
Slide 13: Thank You
Thank You